Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SatiGreen is a branded dried cannabis flower product marketed in Canada as a hybrid strain under Harvest One’s Satipharm line, produced by its subsidiary United Greeneries for distribution through outlets such as Shoppers Drug Mart’s medical cannabis platform.[2][5][6] As with other inhaled cannabis products, its pharmacologic effects are mediated primarily by phytocannabinoids such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) acting on cannabinoid receptors in the endocannabinoid system to produce analgesic, psychoactive, and other neuromodulatory effects, although detailed chemotype, exact THC/CBD ratios, and formal clinical indications have not been disclosed in public regulatory drug dossiers and it is regulated as cannabis rather than as an approved pharmaceutical.[1][2][5][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SatiGreen.